ANTI-BETA-TUBULIN

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .

Monoclonal Anti-μ Tubulin Isotype III (mouse IgG2b isotype) is derived from the SDL.3D10 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice.

Tubulin β 3 class III (TUBB3) plays a vital role in nervous system development and axon guidance. Mutation of the gene encoding protein leads to the ocular motility disorder, congenital fibrosis of the extraocular muscle type 3 (CFEOM3), and various neurological syndromes. Altered expression of the protein affects microtubule dynamics and microtubule-kinesin interactions. Increased expression of TUBB3 is observed in tumor tissues. Decreased expression of TUBB3 can be considered as an important marker for poor prognosis of cutaneous malignant melanoma. TUBB3 is implicated in the suppression of invasive growth of tumor tissue;therefore, it is considered to be a potential target for development of antitumor drugs.